Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
177Lu-TLX250
Telix Innovations
ccRCC
1 trial -
177Lu-TLX591
Telix Innovations
Metastatic Castration-resistant Prostate Cancer
1 trial -
68Ga-PSMA-11
Telix Innovations
PCA
1 trial -
89Zr-Girentuximab
Telix Innovations
Clear Cell Renal Cell Carcinoma
2 trials -
89Zr-TLX250 PET/CT
Telix Innovations
Clear Cell Renal Cell Carcinoma
1 trial -
Ga-68-PSMA-11
Telix Innovations
Prostate Cancer
1 trial -
Standard of Care
Telix Innovations
Metastatic Prostate Cancer
1 trial -
TLX-101-Tx + Lomustine
Telix Innovations
Neoplastic Disease
1 trial -
177Lu girentuximab
Telix Innovations
Advanced Cancer
1 trial -
177Lu-DOTA-TLX591
Telix Innovations
Prostate Cancer
1 trial -
4-L-[131I]iodo-phenylalanine (131I-IPA)
Telix Innovations
Glioblastoma Multiforme
1 trial -
89Zr-Girentuximab
Telix Innovations
Clear Cell Renal Cell Carcinoma (ccRCC)
1 trial -
89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
Telix Innovations
Cervical Cancer
1 trial -
Fluciclovine F18
Telix Innovations
Prostate Adenocarcinoma
1 trial -
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Telix Innovations
Prostate Cancer
1 trial -
Zirconium Zr 89 Girentuximab
Telix Innovations
Clear Cell Renal Cell Carcinoma
1 trial -
131I-IPA
Telix Innovations
Neoplastic Disease
1 trial -
153Sm-DOTMP
Telix Innovations
Bone Pain
1 trial -
177Lu-DOTA-TLX591
Telix Innovations
Metastatic Prostate Cancer
1 trial -
177Lu-TLX250 and Peposertib
Telix Innovations
Solid Tumor, Adult
1 trial -
64Cu-DOTA-TLX592
Telix Innovations
Metastatic Prostate Cancer
1 trial -
68-Ga PSMA11
Telix Innovations
Prostate Adenocarcinoma
1 trial -
89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Telix Innovations
Soft Tissue Sarcoma
1 trial -
89Zr-Girentuximab
Telix Innovations
Clear Cell Renal Carcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources